APT Medical: H1 2026 revenue and profit rose over 25% year-over-year, with strong growth in core segmentsQuartr·6 hours ago688617+1.73%
BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries | ONC Stock NewsStockTitan·1 day ago, 09:00 PMBGNE0.00%ONC+2.31%
Daiwa Reaffirms Their Buy Rating on BeOne Medicines Ltd (6160)Tip Ranks·Aug 14 at 04:15 AMBGNE0.00%06160+1.27%
Shanghai Junshi Biosciences sets board meeting to review interim resultsPUBT·Aug 12 at 04:58 AM01877-1.10%688180-4.60%
Jacobio Pharmaceuticals forecasts H1 net profit at least RMB 600 millionPUBT·Aug 10 at 06:53 AM01167-1.83%AZN+3.42%
BOCOM International Holdings Company Keeps Their Buy Rating on BeOne Medicines Ltd (6160)Tip Ranks·Aug 9 at 09:35 AMBGNE0.00%06160+1.27%
J.P. Morgan Reaffirms Their Buy Rating on RemeGen Co. Ltd. Class H (9995)Tip Ranks·Aug 7 at 07:26 PM09995-1.52%688331-3.90%
CICC Raises BEONE MEDICINES TP to HKD266; 2Q Results BeatAASTOCKS News·Aug 6 at 11:21 PMBGNE0.00%06160+1.27%
BeOne Medicines publishes Q2 clinical trials portfolio presentation detailing pipeline and study updatesPUBT·Aug 5 at 08:16 AMONC+2.31%688235-2.12%
BeOne Medicines Posts Unaudited Q2 2026 Results and Cautions on Preliminary GuidanceTip Ranks·Aug 5 at 05:37 AMONC+2.31%BGNE0.00%
BeOne Medicines: Q2 2026 revenue up 30% to $1.7B, net income up 151%, driven by strong product sales and margin gainsQuartr·Aug 5 at 05:16 AMBGNE0.00%ONC+2.31%
Junshi Biosciences Shareholders Approve H-Share Buyback MandateTip Ranks·Jul 27 at 06:09 AM01877-1.10%688180-4.60%
BeOne Medicines CEO John Oyler reports disposal of shares worth $75.72 millionPUBT·Jul 17 at 04:31 PM06160+1.27%BGNE0.00%
